Peptide Stacks: The Named Blends, Goal-Based Groupings and What the Evidence Actually Says

A stack is simply two or more peptides used together, on the premise that compounds acting through different mechanisms may be complementary. Some stacks have community names — Wolverine, GLOW, KLOW — and are sold as pre-mixed blend vials; others are just combinations people discuss. Almost no stack has been evaluated as a combination in a controlled trial.

In community practice, stacking is usually built around three ideas: pairing compounds with different mechanisms rather than duplicating one, keeping each compound's own reported range rather than escalating because it is combined, and changing one variable at a time so an effect can be attributed. The important structural caveat is that combination evidence generally does not exist, so any stack rationale is inference from the individual compounds. This is descriptive information about what is reported, not a protocol recommendation.

There is no evidence-based answer to this, and any source giving a confident one is going beyond the data. No controlled trial has compared peptide stacks against each other or against single compounds. What can be said is which combinations are most discussed for which research contexts, and what each individual component actually has evidence for — which is how the groupings on this page are organised.

This is the least-studied aspect of stacking. Because combination trials are essentially absent, interactions between peptides in a stack are unstudied rather than known to be safe. The clearest exception is the metabolic category: semaglutide and tirzepatide are prescription medicines with documented interactions and contraindications, and combining them with anything is a clinical decision rather than a stacking choice.

The milligram figure on a blend label is the combined mass of all its peptides, so dividing it by your water volume gives total peptide concentration and nothing useful about any single component. You need the per-component split from the vial's documentation, and vendors do not standardise it — so a volume figure from someone else's vial does not transfer to yours. The KLOW page works a four-component example through this step by step.

Cycling refers to using a compound for a defined period and then taking a break, rather than continuous use. Reported rationales vary by compound — receptor desensitisation for growth-hormone secretagogues, cumulative copper exposure for copper peptides, and simply how the original studies were structured for the Khavinson bioregulators. Reported cycle lengths are described in each compound's own guide; there is no established cycling standard.

No. Medibact supplies USP-grade bacteriostatic water for reconstitution, produced in an FDA-registered U.S. facility, and publishes free educational research guides for 45 compounds. All content is research-use educational reference only — not medical advice and not dose, route or frequency guidance.